⌕
Candel Therapeutics · CADL · Nasdaq
Tenet 45 · Mixed
Compare
$5.81−6.29%At closeTenet 45 · Mixed
$5.81−0.39 (−6.29%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Candel Therapeutics (CADL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CADL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 16, 2026 · 16:43 ETCOMPANY'S OWN WORDS
Candel Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Candel Therapeutics (CADL)

Candel raised $80 million from investors in part to prepare its aglatimagene BLA. On November 12, 2026, the submission slipped to mid-2027 and CADL fell over 26%, prompting an investigation into potential securities law …

CADL −6.3% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 14:58 ET
Candel Therapeutics: Upgrade Despite The Recent Prostate Filing Delay

Candel Therapeutics, Inc. has already shown longer Phase 3 follow-up results that make me more optimistic about their main candidate, aglatimagene. Aglatimagene's disease-free survival seems promising when added to radia…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireNov 16, 2026 · 14:05 ETCOMPANY'S OWN WORDS
Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower – HBSS

SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- On November 13, 2026, investors in Candel Therapeutics (NASDAQ: CADL) saw the price of their shares tumble 26% on the company's announcement that it is delaying the submis…

CADL −6.3% todayRead at source ↗
● Defense WorldNov 15, 2026 · 09:53 ET
Candel Therapeutics, Inc. $CADL Shares Newly Purchased by ACT Capital Partners L.P.

ACT Capital Partners L.P. purchased a new position in shares of Candel Therapeutics, Inc. (NASDAQ: CADL) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Th…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireNov 13, 2026 · 12:29 ET
CADL INVESTIGATION: Candel Therapeutics Investigated for Securities Fraud by Block & Leviton: Investors Should Contact the Firm

Block & Leviton is investigating whether Candel Therapeutics Inc. (CADL) misled investors. Investor with losses should contact the firm to learn more.…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve o…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for lino…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Candel Therapeutics to Present at November Investor Conferences

NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

NEEDHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 09:00 ET
Candel Therapeutics to Present at the SITC 2026 Annual Meeting

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 16:05 ET
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 08:05 ET
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireSep 30, 2026 · 08:30 ET
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve …

CADL −6.3% todayRead at source ↗
● GlobeNewsWireSep 30, 2026 · 08:05 ET
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve …

CADL −6.3% todayRead at source ↗
● Seeking AlphaSep 22, 2026 · 14:50 ET
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized prostate cancer. The company's aglatimagene met the primary endpoint in a pivotal trial, reducing disease recurrence ri…

CADL −6.3% todayRead at source ↗
● Zacks Investment ResearchSep 15, 2026 · 11:15 ET
4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.…

CADL −6.3% todayRead at source ↗
● GlobeNewsWireSep 10, 2026 · 08:05 ET
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve …

CADL −6.3% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 16:05 ET
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve …

CADL −6.3% todayRead at source ↗
● GlobeNewsWireAug 26, 2026 · 08:05 ET
Candel Therapeutics to Present at September Investor Conferences

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve d…

CADL −6.3% todayRead at source ↗

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just CADL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.